Events Details
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability
Wednesday, April 15, 2026
VectorBuilder has introduced MuteFree™ AAV, a high-stability adeno-associated virus (AAV) vector designed to address instability in inverted terminal repeat (ITR) regions, a common issue in gene therapy development. Details of the technology have been published on bioRxiv.
AAV is widely used as a gene delivery platform in therapeutic development. However, challenges in manufacturing consistency and variable treatment performance continue to affect clinical outcomes. One key factor is instability in ITR regions, which are essential for viral genome packaging and transgene expression.
VectorBuilder analysed hundreds of AAV plasmids from academic and industry sources and found that around 40% had mutations in the ITR region. Such mutations can reduce production yields, create variability in manufacturing, and affect therapeutic performance. In some cases, higher doses may be required to achieve the desired effect, which can increase both cost and safety risks.
Current methods to reduce ITR instability often involve specialised E. coli strains, modified culture conditions, or altered ITR sequences. While these approaches may lower mutation rates, they can add complexity and may affect plasmid stability or viral yield.
MuteFree™ AAV has been developed to overcome these limitations. The vector system maintains ITR integrity while remaining compatible with standard E. coli strains and existing manufacturing processes. This allows more consistent AAV production without requiring changes to established development workflows.
Improved stability at the plasmid stage can support more reliable downstream processes. Stable ITR regions help ensure consistent packaging, reduce batch-to-batch variation, and improve confidence as programmes move from research to clinical manufacturing.
The development reflects VectorBuilder’s focus on improving vector design standards and supporting continuity from research to clinical stages. By addressing core design challenges such as ITR stability, the company aims to reduce development risks in genetic medicine.
VectorBuilder will present related findings at the American Society of Gene & Cell Therapy Annual Meeting 2026, where further insights into optimising therapeutic vector design will be shared.
Source: vectorbuilder.com
